Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of UniCAR02-T-CD123 in CD123-positive hematologic malignancies
NL-OMON58637Phase 1Completed
- Sponsor
- AvenCell Therapeutics
- Start
- Nov 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AVC-101 in acute myeloid leukemia (AML) and hematopoietic malignancies, sponsored by AvenCell Therapeutics. Primary endpoint: Primary endpoint(s). Started Nov 2022; status: completed.
02
Drugs
AVC-101
03
Conditions
acute myeloid leukemia (AML)hematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON58637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58637.